Compounds > carbamates

carbamates and batefenterol

carbamates has been researched along with batefenterol in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (91.67)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Baggen, S; Chan, R; Locantore, N; Ludwig-Sengpiel, A; Riley, JH; Wielders, PL1
Ambery, C; Norris, V2
Ambery, C; Bateman, ED; Kornmann, O; Norris, V1
Cazzola, M; Lopez-Campos, JL; Puente-Maestu, L1
Chen, Y; Hegde, SS; Hughes, AD; Jasper, JR; Lee, TW; Mammen, M; Martin, WJ; McNamara, A; Pulido-Rios, MT; Steinfeld, T1
Chen, Y; Hegde, SS; Hughes, AD; Jasper, JR; Jaw-Tsai, S; Lee, TW; Mammen, M; McNamara, A; Pulido-Rios, MT; Steinfeld, T1
Ambery, CL; Chan, R; Ludwig-Sengpiel, A; Riley, JH; Wielders, P1
Ambery, C; Norris, V; Riley, T1
Ambery, C; Daley-Yates, P; Riddell, K1
Ambery, C; Daley-Yates, P; Fuller, T; Georgiou, A; Puri, A; Ramsay, D; Young, G1
Baidoo, C; Castro-Santamaria, R; Crawford, C; Crim, C; Emmett, A; Gotfried, M; Spangenthal, S; Watkins, M1

Trials

9 trial(s) available for carbamates and batefenterol

ArticleYear
A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.
    The European respiratory journal, 2013, Volume: 42, Issue:4

    Topics: Aged; Albuterol; Bronchodilator Agents; Carbamates; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Safety; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Smoking; Spirometry; Treatment Outcome

2013
Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
    Pulmonary pharmacology & therapeutics, 2013, Volume: 26, Issue:5

    Topics: Aged; Albuterol; Bronchodilator Agents; Carbamates; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Ipratropium; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome

2013
Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.
    Pulmonary pharmacology & therapeutics, 2013, Volume: 26, Issue:5

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Bronchodilator Agents; Carbamates; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Scopolamine Derivatives; Time Factors; Tiotropium Bromide; Treatment Outcome

2013
Use of propranolol blockade to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers: results from two randomized trials.
    Drugs in R&D, 2014, Volume: 14, Issue:4

    Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Bronchodilator Agents; Carbamates; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Propranolol; Quinolones; Time Factors; Young Adult

2014
Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial.
    Drugs in R&D, 2015, Volume: 15, Issue:3

    Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones

2015
Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2 -agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers.
    Clinical pharmacology in drug development, 2014, Volume: 3, Issue:4

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Area Under Curve; Biomarkers; Carbamates; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Compounding; Drug Therapy, Combination; Dry Powder Inhalers; Female; Fluticasone; Healthy Volunteers; Humans; Hydrocortisone; Male; Muscarinic Antagonists; Quinolones

2014
Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination.
    Clinical pharmacology in drug development, 2016, Volume: 5, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Androstadienes; Area Under Curve; Bronchodilator Agents; Carbamates; Cross-Over Studies; Drug Combinations; Dry Powder Inhalers; Female; Humans; Male; Middle Aged; Quinolones; Young Adult

2016
Open-Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently.
    Clinical pharmacology in drug development, 2019, Volume: 8, Issue:2

    Topics: Adult; Androstadienes; Area Under Curve; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Quinolones; Young Adult

2019
A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD.
    BMC pulmonary medicine, 2020, May-04, Volume: 20, Issue:1

    Topics: Administration, Inhalation; Aged; Androstadienes; Carbamates; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome

2020

Other Studies

3 other study(ies) available for carbamates and batefenterol

ArticleYear
The MABA approach: a new option to improve bronchodilator therapy.
    The European respiratory journal, 2013, Volume: 42, Issue:4

    Topics: Bronchodilator Agents; Carbamates; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones

2013
Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 351, Issue:1

    Topics: Adrenergic beta-2 Receptor Antagonists; Albuterol; Animals; Bronchodilator Agents; Carbamates; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Drug Evaluation, Preclinical; Guinea Pigs; HEK293 Cells; Humans; Lung; Muscarinic Antagonists; Muscle Relaxation; Muscle, Smooth; Protein Binding; Quinolones; Receptors, Adrenergic, beta; Receptors, Muscarinic; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Tissue Distribution; Trachea

2014
Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmac
    Journal of medicinal chemistry, 2015, Mar-26, Volume: 58, Issue:6

    Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Carbamates; CHO Cells; Cricetulus; Drug Discovery; Guinea Pigs; HEK293 Cells; Humans; Lung; Models, Molecular; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones

2015